IndustryCompany release

Neurocrine third-quarter revenue reaches $1.12bn as Ingrezza sales guidance is raised

🇺🇸 Neurocrine Biosciences Inc (NBIX) · Mon 02 Nov 2026

Neurocrine Biosciences reported total revenue of $1.123bn for Q3 2026 and lifted its full-year Ingrezza net sales guidance to $2.9–2.925bn, with Soleno's Vykat XR now contributing.

Neurocrine Biosciences reported third-quarter 2026 results on 2 November, with total revenue of $1.123bn. The company reported GAAP net income of $207m for the period.

Ingrezza was the largest contributor at $801m. Crenessity brought in $211m, while Vykat XR added $107m. Vykat XR joined the portfolio through Neurocrine's acquisition of Soleno in May 2026.

Neurocrine raised its full-year net sales guidance for Ingrezza to between $2.9bn and $2.925bn.

The company also noted new Phase 1 and Phase 2 study starts and said it will hold an R&D Day on 15 December. The material available gives no further detail on those programmes, and the full release text was not available for this report.

What it means for your team

  • Market-access teams should note that Neurocrine's commercial base now spans three marketed products, including Vykat XR following the Soleno deal.
  • Ingrezza remains the dominant revenue line, and the raised guidance signals continued demand for the product.
  • Teams tracking Neurocrine's pipeline may want to follow the 15 December R&D Day for details on the new early-stage studies.

Company's press release (SEC filing): Neurocrine Biosciences Inc ↗

Article written by VigiEye from the official source (Neurocrine Biosciences Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →